Comparative Analysis of 5-Year Clinical Outcomes and Patterns of Failure of Proton Beam Therapy Versus Intensity Modulated Radiation therapy for Prostate Cancer in the Postoperative Setting

Pound, 1999, Natural history of progression after PSA elevation following radical prostatectomy, J Am Med Assoc, 281, 1591, 10.1001/jama.281.17.1591 Armstrong, 2019 Pisansky TM, Thompson IM, Valicenti RK, D’Amico A V, Selvarajah S. Adjuvant and salvage radiation therapy after prostatectomy: ASTRO/AUA guideline amendment, executive summary 2018. Pract Radiat Oncol. 9:208-213. Patyal, 2007, Dosimetry aspects of proton therapy, Technol Cancer Res Treat, 6, 17, 10.1177/15330346070060S403 Santos, 2019, Comparative toxicity outcomes of proton-beam therapy versus intensity-modulated radiotherapy for prostate cancer in the postoperative setting, Cancer, 125, 4278, 10.1002/cncr.32457 Lee, 2019, Proton-beam therapy after radical prostatectomy: Continued DVH idolatry?, Cancer, 125, 4136, 10.1002/cncr.32456 Santos, 2019, Proton beam therapy after radical prostatectomy, Cancer, 126, 1135, 10.1002/cncr.32642 Paganetti H. Range uncertainties in proton therapy and the role of Monte Carlo simulations. 2012;57:R99-R117. Pollack, 2018, Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiotherapy: The NRG Oncology/RTOG 0534 SPPORT Trial, Int J Radiat Oncol, 102, 1605, 10.1016/j.ijrobp.2018.08.052 Shipley, 2017, Radiation with or without antiandrogen therapy in recurrent prostate cancer, N Engl J Med, 376, 417, 10.1056/NEJMoa1607529 Carrie, 2019, Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): A 112-month follow-up of a phase 3, randomised trial, Lancet Oncol, 20, 1740, 10.1016/S1470-2045(19)30486-3 Deville, 2020, Initial clinical outcomes for prostate cancer patients undergoing adjuvant or salvage poton therapy after radical prostatectomy, Acta Oncol, 59, 1235, 10.1080/0284186X.2020.1766698 Tomé, 2002, On cold spots in tumor subvolumes, Med Phys, 29, 1590, 10.1118/1.1485060 Lomax, 2001, Intensity modulated proton therapy: A clinical example, Med Phys, 28, 317, 10.1118/1.1350587 Carrie, 2016, Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): A randomised, multicentre, open-label phase 3 trial, Lancet Oncol, 17, 747, 10.1016/S1470-2045(16)00111-X Verma, 2016, A systematic review of the cost-effectiveness studies of proton radiotherapy, Cancer, 122, 1483, 10.1002/cncr.29882 Verma, 2018, Quality of life and patient-reported outcomes following proton radiation therapy: A systematic review, J Natl Cancer Inst, 110, 10.1093/jnci/djx208 Pan, 2018, Comparative toxicities and cost of intensity-modulated radiotherapy, proton radiation, and stereotactic body radiotherapy among younger men with prostate cancer, J Clin Oncol, 36, 1823, 10.1200/JCO.2017.75.5371 Chandra, 2015, Age, comorbidity, and the risk of prostate cancer-specific mortality in men with biopsy Gleason score 4+3: Implications on patient selection for multiparametric MRI, Clin Genitourin Cancer, 13, 400, 10.1016/j.clgc.2015.03.001 Russo, 2012, Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM), BJU Int, 110, 973, 10.1111/j.1464-410X.2012.11470.x